Newsletter | November 16, 2026

11.16.26 -- The CDMO Partnership Advantage: How Sponsors Earn Priority And Drive Shared Success

SPONSOR

Webinar: Mission Control For Biologics Tech Transfer: Guiding process performance across sites, scales, and bioreactor systems

Tech transfer isn’t just moving a process from one place to another. It’s about ensuring process understanding and control can withstand changes in scale, equipment, sites, and teams. Explore how bioreactor characterization, scale-down models, in-silico modeling, and cross-site collaboration can uncover uncertainty before it becomes manufacturing risk and help protect product quality and timelines. Click here to learn more.

INDUSTRY INSIGHTS

Biotech's Dirty Little Secret: The Hidden Cost Of Manual Roller Bottles

Roller bottles are essential for adherent cell culture, but manual handling can limit efficiency. Explore automation and closed systems to improve scalability, sterility, and compliance.

From Sequence To Scale In Seven Months

Accelerate recombinant protein development from sequence to scale while maintaining stable expression, manufacturing efficiency, and critical quality attributes.

A CCS Is A Purpose-Built Machine, Not A Black Box

Learn how to transform your contamination control strategy into a dynamic operational framework that identifies risks and strengthens facility control.

FEATURED EDITORIAL

The CDMO Partnership Advantage: How Sponsors Earn Priority And Drive Shared Success

Subpar customer service at CDMOs is no longer something sponsors tolerate; there’s enough competition where they can move on. The other side of the coin is how difficult sponsors sink to the bottom of CDMO priorities; providers also have options. Here's an analysis less about technical components of outsourcing, and more on mutual satisfactions from working together to fulfill contractual arrangements and missions.

Securing Pharma Glass Supply In An Era Of Energy Volatility

Europe's glass manufacturers, including those making pharmaceutical lab glassware, have experienced a series of energy shocks. Many have adopted sustainability practices.

INDUSTRY INSIGHTS CONTINUED

Unlocking Challenging Targets With Macrocycle DNA-Encoded Libraries

Discover how macrocycle DNA-encoded libraries can uncover new opportunities for challenging targets and help researchers translate promising screening hits into starting points for drug discovery.

How To Prepare For Risk-Based Biological Reactivity Testing

Biological reactivity testing is moving from material classification toward risk-based evaluation, where chemistry data, exposure, and application determine what evidence is enough for each material.

Data-Centric Organoid Services For Predictive Drug Response

Patient-derived organoids are gaining traction as translational tools in oncology, but their value depends on the quality and context of the data they generate, not the models alone.

Bridging Discovery, Developability, And Commercial Reality

Driven by metabolic and oncology successes, the expanding peptide therapeutics market faces critical challenges requiring early, customized drug product development, stability, and safety strategies.

Strategic Approaches On The Path To GMP Manufacture

Tech transfer is a critical opportunity to establish a strategy for process performance qualification, mitigate late-stage obstacles, and streamline the pathway to clinical and commercial production.

Best Practices For Optimizing Success In Sterile Drug Manufacturing

Streamline sterile manufacturing tech transfer with early planning, aligned teams, and proactive risk management to reduce delays and ensure consistent, compliant production.

Overcome Early Development Challenges Before They Impact Your Program

Poor manufacturability and immunogenicity can delay development. Learn how early developability assessments support IND readiness.

BIOSECURE, Tariffs, And The New CDMO Reality For Biopharma Innovators

Secure domestic or diversified biopharma manufacturing to protect therapeutic development from supply chain disruptions, rising costs, and legislative tariff impacts.

The European CDMO Model, Powering Biologics Innovation

Europe’s integrated CDMO model is reshaping biologics development by aligning early science, manufacturing, and quality to accelerate scalable, compliant therapies from concept to clinic.

SPONSOR

Webinar: Beyond Destination and Delivery: Designing a Distribution Testing Program

Can your pharmaceutical packaging withstand the journey to patients? From vibration and impact to temperature changes and handling, distribution hazards can compromise product quality and package integrity. Join this webinar to explore ASTM and ISTA testing, learn how to design distribution simulations, and discover how pre- and post-test evaluations assess packaging performance and support product protection throughout the supply chain. Click here to learn more.

SOLUTIONS

USP Purified Water: Best Practices For Pharma

We Navigate You Through Drug Development

End-To-End Large Molecule Solutions For Complex Biologics

Advancing Sterile Fill-Finish With Speed And Flexibility

Annex-1 Compliant Robotic Aseptic Powder Fill/Finish Solution

Large-Scale Cell Culture Multi-Product Facility

OUTSOURCED PHARMA CAPABILITIES UPDATE

Find Your New CDMO At Outsourced Pharma Capabilities Update

CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.

Connect With Outsourced Pharma: